Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 110

1.

Sofosbuvir-based treatment regimens for chronic, genotype 1 hepatitis C virus infection in U.S. incarcerated populations: a cost-effectiveness analysis.

Liu S, Watcha D, Holodniy M, Goldhaber-Fiebert JD.

Ann Intern Med. 2014 Oct 21;161(8):546-53. doi: 10.7326/M14-0602.

PMID:
25329202
[PubMed - indexed for MEDLINE]
2.

Cost-effectiveness analysis of sofosbuvir plus peginterferon/ribavirin in the treatment of chronic hepatitis C virus genotype 1 infection.

Saab S, Gordon SC, Park H, Sulkowski M, Ahmed A, Younossi Z.

Aliment Pharmacol Ther. 2014 Sep;40(6):657-75. doi: 10.1111/apt.12871. Epub 2014 Jul 28.

PMID:
25065960
[PubMed - indexed for MEDLINE]
3.

Cost-effectiveness of Telaprevir combination therapy for chronic hepatitis C.

Brogan AJ, Talbird SE, Thompson JR, Miller JD, Rubin J, Deniz B.

PLoS One. 2014 Mar 6;9(3):e90295. doi: 10.1371/journal.pone.0090295. eCollection 2014.

PMID:
24603445
[PubMed - indexed for MEDLINE]
Free PMC Article
4.

Impact of interferon free regimens on clinical and cost outcomes for chronic hepatitis C genotype 1 patients.

Younossi ZM, Singer ME, Mir HM, Henry L, Hunt S.

J Hepatol. 2014 Mar;60(3):530-7. doi: 10.1016/j.jhep.2013.11.009. Epub 2013 Nov 19.

PMID:
24269472
[PubMed - indexed for MEDLINE]
5.

Cost-effectiveness of telaprevir in combination with pegylated interferon alpha and ribavirin in previously untreated chronic hepatitis C genotype 1 patients.

Cure S, Bianic F, Gavart S, Curtis S, Lee S, Dusheiko G.

J Med Econ. 2014 Jan;17(1):65-76. doi: 10.3111/13696998.2013.860033. Epub 2013 Nov 18.

PMID:
24160335
[PubMed - indexed for MEDLINE]
6.

Pharmacoeconomic analysis of the treatment of chronic hepatitis C with peginterferon alfa-2a or peginterferon alfa-2b plus ribavirin in Spain.

Turnes J, Romero-Gómez M, Planas R, Solà R, García-Samaniego J, Diago M, Crespo J, Calleja JL, Rubio-Terrés C, Ventayol P.

Gastroenterol Hepatol. 2013 Nov;36(9):555-64. doi: 10.1016/j.gastrohep.2013.08.003. Epub 2013 Oct 9.

PMID:
24119723
[PubMed - indexed for MEDLINE]
7.

Cost-effectiveness of telaprevir in combination with pegylated interferon alpha and ribavirin in treatment-experienced chronic hepatitis C genotype 1 patients.

Cure S, Bianic F, Gavart S, Curtis S, Lee S, Dusheiko G.

J Med Econ. 2014 Jan;17(1):77-87. doi: 10.3111/13696998.2013.844159. Epub 2013 Nov 21.

PMID:
24032626
[PubMed - indexed for MEDLINE]
8.

Cost-effectiveness analysis of triple therapy with protease inhibitors in treatment-naive hepatitis C patients.

Blázquez-Pérez A, San Miguel R, Mar J.

Pharmacoeconomics. 2013 Oct;31(10):919-31. doi: 10.1007/s40273-013-0080-3.

PMID:
24000086
[PubMed - indexed for MEDLINE]
9.

Protease inhibitors for hepatitis C: economic implications.

Turner SJ, Brown J, Paladino JA.

Pharmacoeconomics. 2013 Sep;31(9):739-51. doi: 10.1007/s40273-013-0073-2. Review.

PMID:
23839698
[PubMed - indexed for MEDLINE]
10.

A multidisciplinary support programme increases the efficiency of pegylated interferon alfa-2a and ribavirin in hepatitis C.

Carrión JA, Gonzalez-Colominas E, García-Retortillo M, Cañete N, Cirera I, Coll S, Giménez MD, Márquez C, Martin-Escudero V, Castellví P, Navinés R, Castaño JR, Galeras JA, Salas E, Bory F, Martín-Santos R, Solà R.

J Hepatol. 2013 Nov;59(5):926-33. doi: 10.1016/j.jhep.2013.06.019. Epub 2013 Jun 26.

PMID:
23811030
[PubMed - indexed for MEDLINE]
11.

New proposal for response-guided peg-interferon-plus-ribavirin combination therapy for chronic hepatitis C virus genotype 2 infection.

Abe H, Aida Y, Ishiguro H, Yoshizawa K, Seki N, Miyazaki T, Itagaki M, Sutoh S, Ika M, Kato K, Shimada N, Tsubota A, Aizawa Y.

J Med Virol. 2013 Sep;85(9):1523-33. doi: 10.1002/jmv.23626. Epub 2013 Jun 17.

PMID:
23775277
[PubMed - indexed for MEDLINE]
12.

Boceprevir for previously untreated patients with chronic hepatitis C Genotype 1 infection: a US-based cost-effectiveness modeling study.

Ferrante SA, Chhatwal J, Brass CA, El Khoury AC, Poordad F, Bronowicki JP, Elbasha EH.

BMC Infect Dis. 2013 Apr 27;13:190. doi: 10.1186/1471-2334-13-190.

PMID:
23621902
[PubMed - indexed for MEDLINE]
Free PMC Article
13.

Cost-effectiveness analysis of antiviral treatment in liver transplant recipients with HCV infection.

Logge C, Vettorazzi E, Fischer L, Nashan B, Sterneck M.

Transpl Int. 2013 May;26(5):527-34. doi: 10.1111/tri.12085. Epub 2013 Mar 21.

PMID:
23517333
[PubMed - indexed for MEDLINE]
14.

Cost-effectiveness analysis of boceprevir for the treatment of chronic hepatitis C virus genotype 1 infection in Portugal.

Elbasha EH, Chhatwal J, Ferrante SA, El Khoury AC, Laires PA.

Appl Health Econ Health Policy. 2013 Feb;11(1):65-78. doi: 10.1007/s40258-012-0007-8.

PMID:
23355388
[PubMed - indexed for MEDLINE]
15.

Assessing the cost utility of response-guided therapy in patients with chronic hepatitis C genotype 1 in the UK using the MONARCH model.

McEwan P, Kim R, Yuan Y.

Appl Health Econ Health Policy. 2013 Feb;11(1):53-63. doi: 10.1007/s40258-012-0002-0.

PMID:
23329380
[PubMed - indexed for MEDLINE]
16.

Assessing the cost-effectiveness of treating chronic hepatitis C virus in people who inject drugs in Australia.

Visconti AJ, Doyle JS, Weir A, Shiell AM, Hellard ME.

J Gastroenterol Hepatol. 2013 Apr;28(4):707-16. doi: 10.1111/jgh.12041.

PMID:
23173753
[PubMed - indexed for MEDLINE]
17.

Cost-effectiveness of truncated therapy for hepatitis C based on rapid virologic response.

Gellad ZF, Muir AJ, McHutchison JG, Sievert W, Sharara AI, Brown KA, Flisiak R, Jacobson IM, Kershenobich D, Manns MP, Schulman KA, Reed SD.

Value Health. 2012 Sep-Oct;15(6):876-86. doi: 10.1016/j.jval.2012.06.010. Epub 2012 Aug 9.

PMID:
22999138
[PubMed - indexed for MEDLINE]
18.

New protease inhibitors for the treatment of chronic hepatitis C: a cost-effectiveness analysis.

Liu S, Cipriano LE, Holodniy M, Owens DK, Goldhaber-Fiebert JD.

Ann Intern Med. 2012 Feb 21;156(4):279-90. doi: 10.7326/0003-4819-156-4-201202210-00005.

PMID:
22351713
[PubMed - indexed for MEDLINE]
Free PMC Article
19.

Twelve-week posttreatment follow-up to predict sustained virologic response for recurrent hepatitis C infection in liver recipients.

Campos-Varela I, Castells L, Esteban JI, Bes M, Rodríguez-Frías F, Sapisochin G, Allende H, Charco R, Esteban R.

Transplantation. 2012 Feb 27;93(4):450-3. doi: 10.1097/TP.0b013e318240e9dd.

PMID:
22262129
[PubMed - indexed for MEDLINE]
20.

Management of chronic hepatitis C infection in children.

Porto AF, Tormey L, Lim JK.

Curr Opin Pediatr. 2012 Feb;24(1):113-20. doi: 10.1097/MOP.0b013e32834eb73f. Review.

PMID:
22157364
[PubMed - indexed for MEDLINE]
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk